TrialLancet (London, England)2019

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Steven Horwitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.